Fungal-Derived Drugs Have Unexpected “Reaction”

GEN | September 24, 2019

A class of fungal derived compounds, prenylated indole alkaloids, were first discovered in the 1970s. Since then, they have attracted considerable interest for their wide range of potential applications as useful drugs. One compound is already used worldwide as an antiparasitic for livestock. Now, researchers at the University of Michigan Life Sciences Institute (LSI) has solved a nearly 50-year-old mystery regarding how nature produces these bioactive chemical compounds. Prenylated indole alkaloids such as the calmodulin-inhibitory malbrancheamides and anthelmintic paraherquamides, the authors note, have great structural diversity. Understanding how the fungi build these chemicals is essential to reproducing them and creating variants in the lab for new applications. The fungi’s enzymes use very simple building blocks to build the complex molecule. But despite the longstanding knowledge about these compounds, researchers have not been able to tease apart the precise enzymes and reactions that the fungi use to produce them.

Spotlight

Biotechnology products manufactured by Titan Biotech Ltd. It is one of the leading manufacturer and supplier companies in India that offers a wide range of biological products, which used for different type application.

Spotlight

Biotechnology products manufactured by Titan Biotech Ltd. It is one of the leading manufacturer and supplier companies in India that offers a wide range of biological products, which used for different type application.

Related News

INDUSTRY OUTLOOK

Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, modified variant of IL-10 with enhanced durability properties over the naturally occurring wild-type cytokine. XT-150 is currently being evaluated in a Phase 2b study for moderate-to-severe pain caused by osteoarthritis of the knee, a Phase 1/2a study for peripheral neuropathic pain and a study for facet joint syndrome is expected to be initiated by end of year. While serving as milestones along a potential route to approval for each of these indications, the studies also provide valuable safety and efficacy data to guide future clinical development for additional indications currently in the IND-enabling stage. “We are proud to lead Xalud’s Series C financing and continue to support their efforts to build a leading gene therapy company that will address a significant unmet need in the field of chronic inflammatory diseases,” said Paul Manning, chief executive officer and chairman of PBM Capital. “Xalud has assembled an experienced leadership team, supported by diverse and distinguished strategic advisors, who have made strides in progressing their clinical programs and exploring additional indications with large potential.” About Xalud Therapeutics Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of IL-10, that addresses pathologic inflammation and pain.

Read More

MEDTECH

Novozymes and Saipem enter collaboration agreement to create a more sustainable CO2 capture

Novozymes | December 13, 2021

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzymes while further optimizing the process through enzymes innovation. Enzymatic carbon capture is more sustainable in environmental terms and more cost-effective compared to traditional CO2 capture processes. In fact, it is based on the use of enzymes that require the input of heat at lower temperatures and a significantly moderate use of chemicals, energy and, consequently, cuts down the production of harmful waste. Furthermore, this process is more reliable, as the carbonates and enzymes, being low corrosion materials, minimize the deterioration of equipment. Saipem and Novozymes are mutually satisfied with the signed agreement which constitutes an important step towards realizing innovative solutions for the reduction of greenhouse gas emissions. In fact, thanks to Saipem's expertise in CO2 capture and storage technologies and Novozymes' cutting-edge enzymes solutions, the two companies can make the enzymatic carbon capture process highly competitive on the market of traditional amine processes. “This collaboration is an important step towards more sustainable solutions for lowering greenhouse gas emissions. Enzymatic carbon capture has the potential to replace resource-heavy processes with energy-efficient, biological processes, providing both environmental and financial benefits while accelerating the battle against climate change,” Amy Byrick, Executive Vice President of Strategy & Business Transformation at Novozymes About Novozymes Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future.

Read More

CELL AND GENE THERAPY

Curi Bio Closes $10M Series A in Oversubscribed Round

Curi Bio Inc. | December 30, 2021

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform. “Curi Bio is thrilled to partner with the distinguished teams at UTC Investment, DS Asset Management, and Dynamk Capital to fuel our next stage of growth. To discover new therapies requires human-relevant disease models. Curi is working to close the gap between preclinical results and clinical outcomes, not only in small molecule discovery, but also in frontier areas like next-generation genetic medicines and cell therapies.” Michael Cho, JD, CEO of Curi Bio With costs to develop a single new medicine now exceeding $2Bn, the need for more human-relevant disease models to improve translational efficiency in the drug development process has never been greater. Curi’s core platform – the Curi Engine™ – integrates human stem cells, tissue specific biosystems, and A.I./M.L.-enabled data analysis to accelerate the discovery and development of new therapeutics. With this three-pronged strategy — human cells, systems and data — Curi is rapidly becoming a market leader in creating high-fidelity models of human diseases for drug discovery, especially for striated muscle, including cardiac and skeletal muscle, and neuromuscular models. “Curi Bio’s technology platforms create significant value for pharma and biotech companies by accelerating discovery timelines and increasing the chances of success for new therapies in development,” said Dr. Gustavo Mahler, Managing Partner, Dynamk Capital. “We look forward to strong growth in Curi Bio’s customer portfolio.” Curi Bio’s core technologies and products include NanoSurface™ Plates for structural maturation, Cytostretcher™ cell-stretching instruments, and the Mantarray platform for contractility analysis. The Mantarray platform enables researchers to generate and analyze 3D engineered human muscle tissues, providing clinically relevant functional readouts, and reducing reliance on poorly predictive animal models. Curi also offers a suite of customized research services utilizing the Curi Engine, including new assay and model development and phenotypic screening. Curi Bio counts all of the top-ten global pharmaceutical companies among its clients, customers, and partners. About Curi Bio Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a seamless, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. The company’s proprietary technologies are supported by over 100 publications and 19 patents. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.

Read More